MEIP MEI Pharma Inc.

3.2
-0.1  -3%
Previous Close 3.3
Open 3.31
Price To Book 6.04
Market Cap 228129472
Shares 71,290,460
Volume 277,094
Short Ratio
Av. Daily Volume 156,460

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 updated data due by the end of 2019.
Pracinostat in combination with Vidaza
High-risk Myelodysplastic Syndrome (MDS)
Phase 2 topline data released late March 2015 did not meet primary endpoint
Pracinostat in combination with Vidaza
First line intermediate-2 or high-risk Myelodysplastic Syndrome
Ongoing
Pracinostat and Vidaza or Dacogen
Myelodysplastic Syndrome
Phase 1b presentation at ASCO June 3, 2019, 8am CT.
ME-401
Relapsed/refractory Follicular Lymphoma/Chronic Lymphocytic Leukemia (CLL)
Phase 1 final data due at ASCO June 1, 2019, 8am.
ME-344
HER2-negative Breast Cancer
Phase 3 ongoing.
Pracinostat in combination with Vidaza
Phase 1 data due around YE 2019.
Voruciclib
B-Cell Malignancies

Latest News

  1. MEI Pharma to Present New Clinical Results on ME-401 and ME-344 Programs at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
  2. MEI Pharma Reports Third Quarter Fiscal Year 2019 Results and Operational Highlights
  3. Earnings Preview: MEI Pharma (MEIP) Q3 Earnings Expected to Decline
  4. How Does MEI Pharma, Inc. (NASDAQ:MEIP) Affect Your Portfolio Volatility?
  5. 2 Biotech Stock Picks From Legendary Investor Joseph Edelman
  6. MEI Pharma to Present at the 18th Annual Needham Healthcare Conference
  7. MEI Pharma to Present at the 29th Annual Oppenheimer Healthcare Conference
  8. A Holistic Look At MEI Pharma, Inc. (NASDAQ:MEIP)
  9. MEI Pharma Reports Second Quarter Fiscal Year 2019 Results and Operational Highlights
  10. MEI Pharma (MEIP) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
  11. What Percentage Of MEI Pharma, Inc. (NASDAQ:MEIP) Shares Do Insiders Own?
  12. Phase 2 Interim Data Evaluating the Combination of Pracinostat and Azacitidine in Patients with Myelodysplastic Syndrome Presented at the 2018 American Society of Hematology Annual Meeting
  13. MEI Pharma Presents Clinical Data from Ongoing Phase 1b Study of ME-401 in Patients with Indolent B-Cell Malignancies at the 2018 American Society of Hematology Annual Meeting
  14. MEI Pharma Presents Preclinical Data Demonstrating Voruciclib Synergistically Induces Apoptosis in Combination with Venetoclax in Acute Myeloid Leukemia Cells at the 2018 American Society of Hematology Annual Meeting
  15. Is MEI Pharma Inc’s (NASDAQ:MEIP) CEO Paid At A Competitive Rate?
  16. Market Trends Toward New Normal in Lightbridge, MEI Pharma, Good Times Restaurants, Lilis Energy, Microbot Medical, and S&W Seed — Emerging Consolidated Expectations, Analyst Ratings
  17. MEI Pharma Sees Hammer Chart Pattern: Time to Buy?
  18. MEI Pharma Reports First Quarter Fiscal Year 2019 Results and Operational Highlights
  19. Will MEI Pharma (MEIP) Report Negative Earnings Next Week? What You Should Know
  20. MEI Pharma To Present at Stifel 2018 Healthcare Conference